The Fifth Hospital of Xiamen & Xiamen University, Xiamen, China.
Zhongshan Hospital, Xiamen University, Xiamen, China.
BMC Genomics. 2023 Jul 24;24(1):414. doi: 10.1186/s12864-023-09458-3.
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive liver fat deposition, and progresses to liver cirrhosis, and even hepatocellular carcinoma. However, the invasive diagnosis of NAFLD with histopathological evaluation remains risky. This study investigated potential genes correlated with NAFLD, which may serve as diagnostic biomarkers and even potential treatment targets.
The weighted gene co-expression network analysis (WGCNA) was constructed based on dataset E-MEXP-3291. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to evaluate the function of genes.
Blue module was positively correlated, and turquoise module negatively correlated with the severity of NAFLD. Furthermore, 8 driving genes (ANXA9, FBXO2, ORAI3, NAGS, C/EBPα, CRYAA, GOLM1, TRIM14) were identified from the overlap of genes in blue module and GSE89632. And another 8 driving genes were identified from the overlap of turquoise module and GSE89632. Among these driving genes, C/EBPα (CCAAT/enhancer binding protein α) was the most notable. By validating the expression of C/EBPα in the liver of NAFLD mice using immunohistochemistry, we discovered a significant upregulation of C/EBPα protein in NAFLD.
we identified two modules and 16 driving genes associated with the progression of NAFLD, and confirmed the protein expression of C/EBPα, which had been paid little attention to in the context of NAFLD, in the present study. Our study will advance the understanding of NAFLD. Moreover, these driving genes may serve as biomarkers and therapeutic targets of NAFLD.
非酒精性脂肪性肝病(NAFLD)的特征是肝脏脂肪沉积过多,并进展为肝硬化,甚至肝细胞癌。然而,用组织病理学评估进行 NAFLD 的有创诊断仍然存在风险。本研究探讨了与 NAFLD 相关的潜在基因,这些基因可能作为诊断生物标志物,甚至是潜在的治疗靶点。
基于数据集 E-MEXP-3291 构建加权基因共表达网络分析(WGCNA)。进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析,以评估基因的功能。
蓝色模块与 NAFLD 的严重程度呈正相关,而绿松石模块与 NAFLD 的严重程度呈负相关。此外,从蓝色模块和 GSE89632 中的重叠基因中鉴定出 8 个驱动基因(ANXA9、FBXO2、ORAI3、NAGS、C/EBPα、CRYAA、GOLM1、TRIM14)。从绿松石模块和 GSE89632 的重叠中又鉴定出另外 8 个驱动基因。在这些驱动基因中,C/EBPα(CCAAT/enhancer binding protein α)最为显著。通过免疫组织化学验证 C/EBPα 在 NAFLD 小鼠肝脏中的表达,我们发现 C/EBPα 蛋白在 NAFLD 中显著上调。
我们鉴定了与 NAFLD 进展相关的两个模块和 16 个驱动基因,并在本研究中证实了 C/EBPα 的蛋白表达,这在 NAFLD 背景下尚未得到重视。我们的研究将加深对 NAFLD 的认识。此外,这些驱动基因可能作为 NAFLD 的生物标志物和治疗靶点。